ArticleAmerican journal of clinical pathology2020
Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States.
Article in American journal of clinical pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 52 citations in OpenAlex.
- Effectiveness analysis and clinical application potential exploration of combined detection of PAX1/JAM3 gene methylation in early diagnosis of cervical precancerous lesions.Clinical epigenetics · 2026Article
- Associations of HIV RNA Viral Load, CD4 Counts, HPV Detection, and Cytology Support Co-Testing for Cervical Cancer Screening Among Women Living with HIV.HIV/AIDS (Auckland, N.Z.) · 2026Article
- Diagnostic value of cytology in detecting human papillomavirus-independent cervical malignancies: a nation-wide study in Korea.Journal of pathology and translational medicine · 2025Article
- Comparative Oncologic Outcomes in High-Risk Human Papillomavirus-Positive and -Negative Cervical Intraepithelial Neoplasia.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Human papillomavirus prevalence and genotype distribution among 30,147 screened women and 3,362 cervical cancer patients in China: a retrospective study.Virology journal · 2025Article
- HPV-DNA testing from self-sampled menstrual blood using M-strip: A proof-of-concept study on feasibility & acceptance of a novel biosampling method.The Indian journal of medical research · 2025Article
- High Grade Squamous Intraepithelial Lesion (HSIL) Positive Disease Risk Nomogram Model: A Single Centre Retrospective Analysis.International journal of women's health · 2025Article
- Comparison of the SureXFrontiers in oncology · 2025Article
- Effect of different types of smoking on oral health and on cellular changes in oral mucosa.The Saudi dental journal · 2024Article
- Biomarkers in Cancer Detection, Diagnosis, and Prognosis.Sensors (Basel, Switzerland) · 2023Review
- Impact of HPV testing in opportunistic cervical screening: Support for primary HPV screening in the United States.International journal of cancer · 2023Article
- Cervical Cancer Prevention in Rural Areas.Annals of global health · 2023Review
- A Comparative Analysis of Deep Learning Models for Automated Cross-Preparation Diagnosis of Multi-Cell Liquid Pap Smear Images.Diagnostics (Basel, Switzerland) · 2022Article
- Co-testing in cervical screening among 40- to 42-year-old women is unreasonable.Acta obstetricia et gynecologica Scandinavica · 2022Article
- Cervical Screening Performance.American journal of clinical pathology · 2021Article
- Cotesting in Cervical Cancer Screening.American journal of clinical pathology · 2021Article
- Are CIN3 risk or CIN3+ risk measures reliable surrogates for invasive cervical cancer risk?Journal of the American Society of CytopathologyArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesGiven the recent debate challenging the contribution of cytology in cervical screening, we evaluated results of liquid-based cytology (LBC) and human papillomavirus (HPV) testing in cotesting preceding cervical cancer (CxCa) and precancer diagnoses in a national, heterogeneous population.
methodsWe assessed the results of cotesting, performed by Quest Diagnostics, in 13,633,071 women 30 years and older, tested 2010 to 2018. Cotest results preceding CxCa or precancer diagnoses were analyzed and stratified by histopathology.
resultsAmong all screening results, 1,615 cotests preceded 1,259 CxCa diagnoses, and 11,164 cotests preceded 8,048 cervical precancer diagnoses. More women who were subsequently diagnosed with CxCa within 1 year were identified by the LBC result than by the HPV result (85.1%, 1,015/1,193 vs 77.5%, 925/1,193). Among all women with CxCa, the overall rate of nondetection was 13.1% (212/1,615) for cotesting results (LBC negative/HPV negative) and this rate increased substantially when testing exceeded 12 months compared to within 1 year prediagnosis of either CxCa or precancer.
conclusionsAnalysis of 9-year cotest results from a national reference laboratory confirms the value of LBC element in cotesting. This supports that LBC/HPV cotesting enhances screening for the identification of CxCa in women 30 years and older, more so than LBC or HPV alone within cotesting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.